Clinical trial · Interventional
Cryopreserved Ovarian Tissue Transplantation in Patients Who Have Survived Sarcomas and Hematological Tumors
Safety Assessment Of Cryopreserved Ovarian Tissue Transplantation In Patients Who Have Survived Sarcomas And Hematological Tumors
NCT06829654CI-TRIAL-00086113recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study aims to test for the presence or absence of primary tumor-specific tumor markers in ovarian tissue. Therefore, there will be a first phase in which pathology-specific markers will be identified in the patients' diagnostic pathological material by histological, immunohistochemical, and molecular analysis; then, tumor markers will be sought in cryopreserved ovarian tissue.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Haematological Malignancies | — | UNRESOLVED | — |
| Sarcomas | Sarcoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Step 1 | Other | — | UNRESOLVED |
| Step 2 | Other | — | UNRESOLVED |
| Step 3 | Other | — | UNRESOLVED |
| Step 4 | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- OTHER
- label
- Patients who request cryopreservation of ovarian tissue
- description
- Patients who request cryopreservation of ovarian tissue
- interventionNames
- Other: Step 1
- Other: Step 2
- Other: Step 3
- type
- OTHER
- label
- Patients with already cryopreserved ovarian tissue at the criobank
- description
- Patients with already cryopreserved ovarian tissue at the criobank
- interventionNames
- Other: Step 2
- Other: Step 3
- type
- OTHER
- label
- Patients who request ovarian tissue reimplantation
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 38 Years
Show eligibility criteria text
Inclusion Criteria: For all groups: * Patients with Ewing (ES) and synovial (SS) sarcoma, acute lymphoblastic leukemia (LLA), acute myeloid leukemia (LMA), chronic myeloid leukemia (LMC) and myelodysplasia (MDS) * No objection to the procedure of sampling for cryopreservation or reimplantation of ovarian tissue by the patient's reference oncologist (according to PA105) * Obtaining informed consent. Group 1: * Age \>18 and under 38 at the time of cryopreservation * Request for cryopreservation of ovarian tissue at the Laboratory Cryopreservation Ovarian Tissue and Cell Cultures/Criobank IRCCS AOUBO Group 2: * Age \>18 years * Ovarian tissue already collected and cryopreserved at the Laboratory for Cryopreservation of Ovarian Tissue and Cell Cultures/Criobank IRCCS AOUBO Group 3 * Age \> 18 years * Request for reimplantation of cryopreserved ovarian tissue at the Laboratory for Cryopreservation of Ovarian Tissue and Cell Cultures/Criobank IRCCS AOUBO * Early menopause or menstrual irregularities Exclusion Criteria: Group 1 and 3 * Contraindications to laparoscopy * HIV, hepatitis B and C, treponema pallidum and positive PAP tests * Malignant disease involving the ovary or samples to be reimplanted Group 2 None.
References
Publications (0)
Data not yet available
No reference posted for this study.